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ABSTRACT The development of hypertension in the
spontaneously hypertensive rat (SHR) is associated with renal
dysfunction and vasoconstriction. The kidneys ofyoung SHRs
exhibit exaggerated reactivity to angiotensin II (Ang-II) and
attenuated responses to vasodilators that normally activate
the cAMP signal to buffer hormone-induced vasoconstriction.
The present study investigates the mechanism(s) responsible
for this abnormality in activation of the cAMP second-
messenger pathway in hypertensive animals. Renal vascular
reactivity was assessed in 7-week-old anesthetized SHRs and
normotensive Wistar-Kyoto rats. The animals were pre-
treated with indomethacin to block prostanoid production
throughout an experiment. Ang-Il was injected into the renal
artery either alone or mixed with the vasodilator fenoldopam,
a dopamine-receptor agonist. These two opposing vasoactive
agents were administered before and during intrarenal infu-
sion of NaF or cholera toxin, two activators of G proteins that
stimulate cAMP production. The results show that Ang-Il
reduced renal blood flow by 45% in both strains. In Wistar-
Kyoto rats, fenoldopam reduced the Ang-II-induced decrease
in renal blood flow from -45% to -30%. This protective effect
of fenoldopam was increased further during infusion of NaF
or cholera toxin (- 18% or - 19% decrease in renal blood flow).
In SHRs, fenoldopam failed to attenuate Ang II-mediated
vasoconstriction (-45% vs. -44%). In contrast, fenoldopam
effectively blunted the Ang-II-induced vasoconstriction when
it was given concurrently with NaF or cholera toxin (-27 or
-31% decrease in renal blood flow). These findings provide
evidence for defective interaction between receptor coupling
and activation of guanine nucleotide stimulatory factor pro-
teins in the renal microcirculation of 7-week-old SHRs. Such
a deficiency could play an important role in renal dysfunction
associated with the development of genetic hypertension.
Rats developing genetic hypertension, such as the Okamoto-
Aoki strain of spontaneously hypertensive rat (SHR), provide
opportunities for insight into mechanisms involved in the
pathogenesis of essential hypertension in humans. Cross-
transplantation studies indicate that the kidneys play a pivotal
role in the development of hypertension in genetically hyper-
tensive rats (1-3). Alterations in renal vascular resistance,
glomerular filtration rate, renal blood flow, and sodium and
water retention have been described in 6- to 8-week-old SHRs
compared with age-matched control Wistar-Kyoto rats
(WKYs) (4-6). The abnormalities in renal hemodynamics and
function become less pronounced as the hypertension ad-
vances to an established phase in 12-week-old SHRs (7, 8).
Genetic cosegregation studies reveal a direct relationship
between increased renal vascular resistance and arterial hy-
pertension (9).
The mechanism(s) responsible for increased vascular resis-
tance and reactivity have been the subject of intense investi-
gation. Increased renal vascular resistance in adult animals is
proportional to the increase in arterial pressure and may
represent an appropriate autoregulatory response (7). In
contrast, the reduced renal blood flow and glomerular filtra-
tion rate in young SHRs with minimally elevated arterial
pressure are consistent with the participation of vasoconstric-
tor factor(s).
Although circulating and intrarenal levels of renin are
considered normal in SHRs, several lines of evidence support
the notion that the renin-angiotensin system exerts a stronger
than normal influence on the renal circulation in young
SHR(s). Acute and chronic inhibition of angiotensin-
converting enzyme prevents the development of hypertension
in young SHR(s) (10). In previous studies we observed that
renal vascular responses to angiotensin II (Ang-IT) are exag-
gerated in young SHRs compared with those in WKYs
(10-13). This strain difference was not due to differences in
the affinity and/or density of the Ang-II receptors found in the
renal vasculature but rather was due to identified interactions
with other vasoactive substances (12, 13).
The increased vasoconstriction could be caused by reduced
offsetting activity of a vasodilator system. Several renal vaso-
dilators, such as prostaglandins E2 and I2 and the dopamine
(DA1)-agonist fenoldopam, could not buffer the Ang-TI-
induced vasoconstriction in the kidneys of 6- to 8-week-old
SHRs. The same vasodilator agents were, however, able to
almost completely abolish the Ang-II effect in kidneys of
age-matched WKYs (13-15). The abnormality seemed specific
to activators of the cAMP messenger system. Receptor ago-
nists leading to increased nitric oxide production and activa-
tion of the cGMP pathway were equally effective in normo-
tensive and hypertensive strains (13, 14).
The present study examined the mechanisms responsible for
the inability of vasodilator autacoids/paracrine substances to
counteract the Ang-1I-induced vasoconstriction in the renal
vasculature of SHR(s) that are young and in the developmental
phase of hypertension. Our results suggest that this abnormal-
ity is probably due to an impaired activation of a guanine
nucleotide stimulatory protein (G.) coupled to receptors of
agents that normally activate the cAMP pathway. Such a defect
may cause hypertension by acting on vascular smooth muscle
cells and renal tubular epithelial cells.
MATERIALS AND METHODS
Experiments were done on 7-week-old rats of the normoten-
siveWKY and the hypertensive SHR strains obtained from the
Chapel Hill breeding colony. The animals were maintained on
a standard rat chow diet and tap water ad libitum until the
Abbreviations: Ang-II, angiotensin II; SHR, spontaneously hyperten-
sive rat; WKY, Wistar-Kyoto rat; Gs, guanine nucleotide stimulatory
protein.
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night before an experiment. Anesthesia was induced by an i.p.
injection of pentobarbital sodium (65 mg/kg of body wt), and
the animals were placed on a heating table to maintain body
temperature at 37°C. Standard surgical procedures were used
(5, 7, 11-14, 16). Briefly, after a tracheotomy a carotid artery
was cannulated to obtain blood samples and monitor arterial
pressure (Statham P23 Db transducer). A jugular vein was
cannulated for the administration of maintenance infusions, a
cyclooxygenase inhibitor, and supplemental doses of anes-
thetic. Euvolemia was maintained by infusion of iso-oncotic
bovine serum albumin. Midline and subcostal incisions ex-
posed the abdominal aorta and the left kidney. A noncannu-
lating electromagnetic flow probe (1.5-mm circumference,
Carolina Medical Electronics, King, NC) was placed around
the left artery to measure renal blood flow. A tapered and
curved PE-10 catheter was introduced into the left femoral
artery and advanced through the aorta until its tip was
positioned in the left renal artery. This procedure did not
affect renal blood flow. The renal arterial catheter was used for
the local administration of vasoactive agents. After completion
of the surgery, the animals were allowed to stabilize for 1 hr
before starting the measurements.
After the stabilization period, indomethacin (5 mg/kg of
body wt) was administered i.v. to inhibit cyclooxygenase
activity. This dose of indomethacin produces a 60-80% de-
crease in the rate of urinary prostaglandin E2 excretion for at
least 3 hr (11). During the experiment, heparinized isotonic
saline was infused (5 ,ul/min) via the renal arterial catheter. A
Cheminert sample injection valve was used to introduce a
10-,ul bolus of test agent into the infusion line. One minute
before an injection, the rate of saline infusion was increased to
120 ,ul/min to deliver the entire bolus of test agent to the
kidney within 5 sec. After renal blood flow returned to its
baseline level (usually <2 min), the saline infusion was re-
turned to 5 ,ul/min.
The following drugs were used in this study: Ang-II, NaF,
and indomethacin (Sigma), fenoldopam (SmithKline
Beecham), and cholera toxin (Biomol, Plymouth Meeting,
PA). Ang-I1 (2 rg) was injected into the left renal artery either
alone or in a mixture with fenoldopam (10 iqg). The G protein
activators NaF and cholera toxin were infused at low doses (13
qg/min and 1.3 ,ug/min, respectively); they did not affect basal
renal blood flow or arterial pressure. The intrarenal admin-
istration of the G protein activators was started 2 min before
Ang-IT was injected either alone or with fenoldopam and was
continued until the end of each 2-min recording. The time
interval between Ang-II injections was 15 min. To avoid
treatment interactions, only one G protein activator was given
to an animal. Ang-II responsiveness was tested between infu-
sions of NaF or cholera toxin. In all cases, Ang-II produced a
similar decrease in renal blood flow. Thus, G protein activators
produced specific changes in the responsiveness of the renal
vasculature.
The data-acquisition system consisted of an IBM PC-
compatible computer and a 12-bit analog-to-digital converter
(11, 12). Each recording was started when Ang-Il was intro-
duced into the renal artery infusion line. The outputs of the
transducers monitoring arterial pressure and renal blood flow
were sampled at a rate of 100 samples per sec for a period of
2 min. Data were averaged to obtain sec-by-sec estimates of
renal blood flow and arterial pressure, and these averages were
used to estimate renal vascular resistance each sec. The renal
blood flow, arterial pressure, and renal vascular resistance
values were normalized and expressed as a percentage of
baseline values. The baseline was calculated separately for
each injection using the mean values of the corresponding
variables observed during the time between the introduction of
Ang-II into the infusion line and the onset of the renal vascular
response. Plots of normalized arterial pressure, renal blood
flow, and renal vascular resistance as a function of time were
prepared by using the SIGMAPLOT software package. Nonlinear
least-squares estimation was used to fit a smooth curve to each
blood flow and vascular resistance recording as described (11).
The best-fit curve was used to calculate the maximum response
and kinetic parameters, such as the time required to reach the
maximum response and the half-times for constriction and
recovery.
Statistical analyses were done by using the Multivariate
Generalized Linear Hypothesis module of the SYSTAT software
package. Statistical analyses of the maximum changes in renal
blood flow gave similar results, regardless of whether these
changes were expressed as a percentage of the baseline or as
absolute values. P < 0.05 was considered statistically signifi-
cant.
RESULTS
Baseline renal hemodynamic data are summarized in Table 1.
Seven-week-old SHRs were moderately hypertensive com-
pared with age-matched WKY controls. In SHRs, basal renal
flow was reduced and renal vascular resistance was increased
in agreement with previous results (5, 11). Indomethacin
affected neither arterial pressure nor renal blood flow in
WKYs and SHRs, in accordance with earlier results (11).
Injection of Ang-II into the renal artery produced a tran-
sient decrease in renal blood flow and an increase in renal
vascular resistance, without affecting systemic arterial pres-
sure. Because arterial pressure was constant, local changes in
renal blood flow were associated with reciprocal changes in
renal vascular resistance (data not shown). Representative
examples of the renal vascular response to Ang-I1 are shown
in Fig. 1. The maximum vasoconstriction caused by 2 -g of
Ang-I1 was similar in WKYs and SHRs. Renal blood flow was
reduced by 44 ± 2 vs. 45 ± 2% (P > 0.6), in close agreement
with previous observations (11, 12).
Fenoldopam, a dopamine DAl-receptor agonist, was co-
administered with Ang-II intrarenally to determine whether
receptor-mediated stimulation of intracellular cAMP can
buffer the vasoconstrictor effect of Ang-II. The data in Fig. 1A
show that fenoldopam attenuated 50% of the transient renal
vasoconstriction produced by Ang-II in WKY kidneys. The
maximum decrease in renal blood flow observed at 29 sec after
injection was reduced from -52% to -31% of basal renal
blood flow. The buffering effect of fenoldopam could be
blocked by coadministration of the receptor-antagonist SCH-
23390 in a dose-related manner, indicating selective activation
ofvascular DAt receptors. On the other hand, fenoldopam was
ineffective in SHR kidneys (Fig. IB). The maximum response
to the mixture of Ang-II and fenoldopam did not differ from
that of Ang-IT alone in the genetically hypertensive strain.
Table 1. Baseline renal hemodynamic variables in euvolemic
7-week-old WKYs and SHRs
WKY SHR P*
Age, week 7 ± 1 7 ± 1 NS
Body wt, g 196 ± 6 201 ± 1 NS
Arterial pressure,
mmHg 124 ± 2 148 ± 3 <0.001
Renal blood flow,
ml.min-t.(g kidney




(g kidney wt)-1 17.2 ± 0.9 23.5 ± 1.2 <0.001
Hematocrit, mldl-1 46 ± 1 47 ± 1 NS
Rats, no. 14 14
Values are means ± SEM. 1 mmHg = 133 Pa.
*P value of unpaired t test; NS, not statistically significant (P > 0.05).
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FIG. 1. Representative examples of temporal variations in renal
blood flow produced by injection of Ang-II (2 ing) into the renal artery.
Ang-II was administered alone (0) and when mixed with the DAl
dopamine agonist fenoldopam (10 ing) (-and A). The agents were
injected before and during infusion of NaF (- and A, respectively) into
the renal artery. (A) WKY data. (B) SHR data.
Statistical analysis using the best-fitting curve model de-
scribed earlier in Materials and Methods confirmed that
fenoldopam significantly reduced the maximum vasoconstric-
tion produced by Ang-II in seven WKYs (-30 ± 2% vs. -45
+ 3% basal renal blood flow, P < 0.001), but it had no effect
in seven SHRs (-44 ± 2%o vs. -45 ± 2%, P> 0.7) (Fig. 2).
The kinetics describing the transient response to Ang-II when
administered alone and coadministered with fenoldopam did
not differ between SHR and WKY (Table 2). Interestingly,
fenoldopam shortened the half-time of recovery from the
Ang-Il-induced vasoconstriction similarly in WKYs (from 75
+ 3 to 64 ± 4 sec, P < 0.05) and SHRs (from 71 + 3 to 64 ±
2 sec, P < 0.05), even though a strain difference was observed
in the magnitude of the maximum response (Fig. 2) (11, 13).
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FIG. 2. Group averages for the maximum decrease in renal blood
flow produced by intrarenal injection of Ang-II in WKYs (A) and
SHRs (B). Ang-Il was given alone and mixed with the dopamine
DAl-agonist fenoldopam before or during NaF administration. Val-
ues are means ± SEM for seven WKYs and seven SHRs. P < 0.05 for
WKYs vs. SHRs; P < 0.05 for control vs. fenoldopam or vs. fenoldo-
pam plus NaF within strain.
Table 2. Summary of kinetic parameters describing the transient
renal vascular response to Ang-II alone and in a mixture with
fenoldopam before and during intrarenal infusion of NaF or
cholera toxin
Half-time, sec
WKY SHR Rats, no.
Constriction half-time, sec
Ang-II 16 ± 1 16 ± 1 14
Ang-IT + fenoldopam 17 ± 1 17 ± 1 14
Ang-Il + fenoldopam
+ NaF 16 ± 2 17 ± 1 7
Ang-II + fenoldopam
+CTX 17±1 17±1 7
Recovery half-time, sec
Ang-II 75 ± 3 71 ± 3 14
Ang-II + fenoldopam 64 ± 4* 64 ± 2* 14
Ang-II + fenoldopam
+ NaF 64 ± 3* 64 ± 3* 7
Ang-II + fenoldopam
+ CTX 78 ± 4 71 ± 3 7
Values are means ± SEM. CTX, cholera toxin.
*P < 0.05 vs. Ang-II. None of the values differed between SHRs and
WKYs.
Fenoldopam had no effect on the time to maximum vasocon-
striction (29 ± 1 vs. 29 ± 1 sec) in both strains.
Further studies were done to gain insight into the mecha-
nism(s) responsible for this abnormality in vascular reactivity.
We investigated whether the strain difference in the ability of
fenoldopam to buffer the Ang-II-induced renal vasoconstric-
tion could be related to the efficiency of coupling of DAl
receptors to G proteins. For this reason, the renal vasculature
was exposed to NaF, a general activator ofG proteins (17-19).
In the absence of a vasodilator agent, NaF did not affect the
decrease in renal blood flow induced by Ang-II in WKYs (-46
± 4% vs. -45 ± 2%, P > 0.7) or in SHRs (-45 ± 2% vs. -45
± 3%, P > 0.6). An important finding was that a NaF effect
was observed when fenoldopam was injected in combination
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FIG. 3. Representative examples of temporal variations in renal
blood flow produced by injection ofAng-II (2 iqg) into the renal artery.
Angiotensin was administered alone (0) and mixed with the dopamine
DAl-agonist fenoldopam (10 -qg) (- and A). The agents were injected
before and during infusion of cholera toxin (-and A, respectively) into
the renal artery of a WKY (A) or a SHR (B).
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FIG. 4. Group averages for the maximum decrease in renal blood
flow produced by intrarenal injection of Ang-II and Ang-II plus the
dopamine DAl-agonist fenoldopam before or during concurrent
administration of cholera toxin. (A) WKY data. (B) SHR data. Values
are means ± SEMs for seven WKYs and seven SHRs. P < 0.05 for
WKY vs. SHR; P < 0.05 for control vs. fenoldopam or fenoldopam
plus cholera toxin within strain.
more effectively buffered by NaF plus fenoldopam as com-
pared with fenoldopam administration alone. This synergism
occurred in both rat strains. In seven WKYs the mean maxi-
mum decrease in renal blood flow was reduced from -28 ±
2% to -18 ± 2% (P < 0.001) (Figs. 1 and 2). A major
observation was that the combination of NaF and fenoldopam
significantly blunted the Ang-II induced vasoconstriction in
seven SHRs (-27 ± 3% vs. 45 ± 3%, P < 0.001 (Figs. 1 and
2). This result contrasts with the earlier data for the hyper-
tensive strain showing that fenoldopam was ineffective without
NaF.
To determine whether or not a specific family of G proteins
was involved in the buffering effect, other animals were treated
with cholera toxin, a selective activator of G, proteins (17-19).
Representative examples of the renal vascular response to
Ang-II injected alone and in mixture with fenoldopam before
and during cholera toxin infusion are shown in Fig. 3. In
WKYs, fenoldopam blunted the Ang-1I-induced vasoconstric-
tion (-31 ± 2% vs. -44 ± 3%, P < 0.001) (Figs. 3A and 4).
Cholera toxin infusion enhanced the buffering effect of
fenoldopam (-19 ± 3% vs. -31 ± 2%, P < 0.001) (Figs. 3A
and 4). In SHRs, coadministration of fenoldopam with Ang-II
did not alter the renal vasoconstriction produced by Ang-1I
(-44 ± 3% vs. -45 ± 4%) (Fig. 4). In marked contrast,
simultaneous exposure to cholera toxin unmasked a buffering
effect of fenoldopam in the hypertensive strain. As is shown in
Fig. 3B, the transient decrease in renal blood flow was clearly
blunted during infusion of cholera toxin as compared with the
administration of Ang-II plus fenoldopam without cholera
toxin. The average maximum vasoconstriction was signifi-
cantly reduced when the G protein stimulator was adminis-
tered (-31 ± 2% vs. -45 ± 4%, P < 0.01) (Figs. 3B and 4).
The amplifying effect of NaF and cholera toxin appeared
specific for an interaction between the DA1 receptor and Gs
protein. The agents administered into the renal artery by
themselves had no demonstrable effect on basal renal blood
flow, and neither affected the renal vasoconstriction produced
by Ang-II in either strain of rat. In the absence of fenoldopam,
Ang-II-induced decreases in renal blood flow were similar
before and during administration of NaF or cholera toxin.
DISCUSSION
The present study provides important information about the
mechanism(s) by which Ang-II enhances vasoconstriction in
kidneys of rats developing hypertension of genetic origin.
Transient changes in the renal vasculature were monitored
after bolus administration of Ang-I1 into the renal artery of
7-week-old SHRs with age-matched WKYs serving as normo-
tensive controls. The applied technique and data analysis
permitted estimation of local responses of the renal vascula-
ture to vasoactive agents without systemic complications. As a
result, a comprehensive evaluation of intrarenal mechanisms
governing the renal microcirculation in vivo was feasible (11).
Recent studies by our laboratory and other investigators (11,
12, 20) have established that kidneys of young SHRs exhibit
exaggerated reactivity to Ang-I1 compared with normotensive
WKY controls. The fact that treatment of the rats with
indomethacin, a cyclooxygenase inhibitor, increased the Ang-
1I-induced vasoconstriction in WKYs and abolished the strain
difference in vascular reactivity suggests that the action of
endogenous prostaglandins affords protection in WKY, but
not in SHR, kidneys (11).
In support of this hypothesis, intrarenal infusion of authentic
vasodilator prostaglandins E2 and 12 or of their respective
receptor agonists viprostol and iloprost failed to protect
kidneys of the SHR from the Ang-II-induced vasoconstriction,
whereas the same prostanoids effectively blunted -50% of the
effect of Ang-II in WKY kidneys (14). Similar to prostaglan-
dins, the dopamine DAl-receptor agonist fenoldopam signif-
icantly buffered the Ang-II-induced vasoconstriction in WKY,
but not in SHR, kidneys (16)-. On the contrary, acetylcholine
and bradykinin, representing another class of renal vasodila-
tors, effectively attenuated the vasoconstrictor effect of Ang-II
in a dose-dependent fashion in the kidneys of both SHRs and
WKYs (16). The actions of fenoldopam and prostaglandins are
initiated by binding to specific receptors on the surface of
vascular smooth muscle cells. The receptor-ligand complex
stimulates the cAMP pathway through activation of GTP-
binding stimulatory G, proteins. On the other hand, acetyl-
choline and bradykinin primarily act in vivo through endothe-
lial-derived nitric oxide to activate the cGMP pathway. Thus,
the defect seemed to be localized to the cAMP signaling
pathway that would normally respond to several different
receptor agonists.
Our previous studies evaluated the role of cAMP produc-
tion as a mechanism responsible for the failure of fenoldopam
and prostaglandins to buffer the Ang-II effect in SHRs. In vivo
activation of the intracellular cAMP pathway in the renal
resistance vessels was tested by using forskolin (adenylyl
cyclase activation independently of receptor binding) or by
administering dibutyryl-cAMP (cell-membrane permeable
form of cAMP) into the renal artery (16). Both cAMP-
elevating agents buffered the Ang-II-induced vasoconstric-
tion. A similar degree of protection was provided in WKY and
SHR kidneys. These observations indicate that renal vasodi-
lators acting through receptor coupling to activate the cAMP
pathway fail to buffer the Ang-IT-induced vasoconstriction in
SHRs. The defective event in this abnormal transmission of the
signal(s) appears to be localized to a step proximal to activa-
tion of adenylyl cyclase.
The intracellular events preceding adenylyl cyclase activa-
tion are ligand-receptor coupling and receptor-G. protein
interaction. Several lines of evidence argue against the possi-
bility of a strain difference in the first alternative. By design,
the amount of the ligand administered was the same in SHRs
and WKYs in all of our experiments. In addition, radioligand
binding studies revealed no difference in the characteristics
(affinity and/or density) of prostaglandin E2 and prosta-
glandin 12 receptors in isolated glomeruli or preglomerular
resistance vessels between SHRs and WKYs (ref. 14, unpub-
lished observations). Prostaglandin E2 receptor availability
was similar in renal medullary membranes of SHR and WKY,
although the amount of cAMP generated by prostaglandin E2
was 3-fold lower in SHRs (21, 22). Furthermore, the dopamine
Physiology: Chatziantoniou et at
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DAl receptor found in the renal proximal convoluted tubule
displayed similar affinity, density, and molecular mass in SHRs
and WKYs, although the activation of cAMP was attenuated
in SHRs (23).
Our results clearly support the hypothesis of a defective
interaction between receptor and G, protein activation in the
renal vasculature of SHRs. Fenoldopam alone did not coun-
teract the Ang-1I-induced vasoconstriction in SHR kidneys.
Only when the G proteins of the renal vasculature were first
activated was fenoldopam able to buffer the Ang-1I-induced
vasoconstriction in SHRs. It is noteworthy that NaF, an
activator of G proteins in general, had a similar protective
effect to that of cholera toxin, a selective activator of the Gs
family of proteins. This finding indicates that the defective
interaction is specific to receptors coupled to G, proteins.
Raymond (24) has recently reviewed hereditary defects in
signaling through hormone receptor-G protein complexes. To
our knowledge, the present study is the only report of a
defective interaction of receptors linked to activation of in-
tracellular cAMP pathway with their respective Gs proteins in
the renal vasculature of rats developing hypertension. A
similar type of abnormality is apparently expressed in renal
proximal tubular cells as well. Felder and coworkers (23, 25)
have observed abnormal coupling of a DAl receptor to cAMP
generation in proximal convoluted tubules microdissected
from young SHRs. Their biochemical studies of radioligand
binding and adenylyl cyclase activity suggest a primary hered-
itary defect in the interaction of membrane receptors to G
protein activity. Persistent defective coupling in SHRs was
observed while receptor-mediated cAMP generation in WKYs
became stronger with age. Apparent receptor number and
affinity were constant in 3-, 8-, and 20-week-old WKYs, as was
basal, forskolin, and guanyl nucleotide-stimulated adenylate
cyclase activity and DlA receptor mRNA. Interestingly, the
tubular defect was observed in a proximal, but not a collecting
duct, segment. Such a defect in receptor stimulation of cAMP
production could promote hypertension by a dual mechanism.
Attenuated generation of cAMP within the renal vasculature
could result in increased renal vascular resistance, and a similar
defect in cAMP generation in renal tubules could lead to
increased sodium retention. Both of these renal abnormalities
are associated with the initiation and development of hyper-
tension (4, 5).
Further support for our findings and conclusions derives
from a study comparing the function of G proteins in mem-
branes of mesenteric arteries isolated from SHRs and WKYs.
Agents that activate the cAMP pathway through receptor
coupling to G proteins caused a smaller stimulatory response
of cAMP generation in SHRs (26). However, when forskolin
was used to stimulate adenylyl cyclase independent of activa-
tion of cell-surface receptors, the cAMP levels were increased
to an equal extent in SHR and WKY membranes. In addition,
no strain difference was found in the G protein levels of this
tissue, as evidenced by immunoblotting.
In our studies, fenoldopam facilitated the recovery from
transient vasoconstriction after the activation of Ang-1I re-
ceptors. The half-time of recovery after injection of the
mixture of fenoldopam and Ang-IT was similar in SHRs and
WKYs, even though the magnitude of the maximum response
was 2-fold larger in SHRs. A similar observation was made in
earlier studies (12, 14) when several doses of fenoldopam and
prostaglandins were tested. To explain these results we pos-
tulated a dual mechanism of action of renal vasodilators
against the Ang-II-induced vasoconstriction. One part of this
mechanism is considered dependent on cAMP activation and
thereby impacts on the magnitude of the maximum renal
vascular response. The other part is related to the rate of
recovery and may be related to the rate of dephosphorylation
of myosin. SHRs appear to be defective in the first, but not the
second, mechanism (12, 14). Our present results provide
evidence to support this hypothesis. The combination of G
protein activation and fenoldopam did not provide any addi-
tional change of the recovery rate, although the magnitude of
the response to Ang-Il was buffered.
In conclusion, vasodilators that activate the cAMP intracel-
lular signaling pathway are ineffective in counteracting the
vasoconstrictor effect of Ang-II in the renal vasculature of
young SHRs. The cause of this defect is probably related to a
deficient interaction between the cell-surface receptors of
these agents and their respective G, proteins. Such a gener-
alized defect of the renal vasculature could be a major
contributor to the development of genetic hypertension.
Fenoldopam was a gift of SmithKline Beecham. This work was
supported by National Heart, Lung, and Blood Institute Grant-in-Aid
HL-02334. Portions of this work were presented at the 1994 Annual
Meeting of Experimental Biology and have been reported (27).
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